On November 12, 2024, FiscalNote Holdings, Inc. (the “ Company ”) announced a leadership succession whereby Tim Hwang, the company’s current Chairman, Chief Executive Officer, and Co-founder, will transition to Executive Chairman and Josh Resnik, the company’s current President and Chief Operating Officer, will become President and Chief Executive Officer, each effective January 1, 2025.
Departed
Michael Breininger
principal financial officer and principal accounting officer
Michael Breininger, the Company’s Corporate Controller, will no longer serve as the principal financial officer and principal accounting officer of the Company.
Appointed
Ramesh Ramachandran
principal financial officer and principal accounting officer
the Board of Directors of Ocugen, Inc. (the “ Company ”) appointed Ramesh Ramachandran to serve as the Company’s principal financial officer and principal accounting officer
On November 15, 2024, the Company’s Board of Directors (the “Board”) appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company’s Interim Chief Financial Officer, effective immediately.
Departed
Michael J. Grau
Executive Vice President and Chief Financial Officer
On November 13, 2024, Madison Square Garden Entertainment Corp. (the “Company”) and Michael J. Grau, the Company’s Executive Vice President and Chief Financial Officer, agreed that he will be leaving the Company, and effective November 20, 2024, will cease to be Chief Financial Officer.
On November 12, 2024, due to the appointment of Mr. Boggs as Chief Financial Officer of the Company, the Company amended the employment agreement ("Employment Agreement") dated December 2, 2021, with Mr. Boggs
On November 15, 2024, in relation to the retirement of Jim Stark from the Chief Financial Officer role, Mr. Stark and the Company entered into a Confidential Severance Agreement and Release
On November 15, 2024, M. Shane Bell notified the Board of Directors of First National Corporation (the “Company”) and its wholly-owned subsidiary, First Bank (the “Bank”), of his resignation as Executive Vice President and Chief Financial Officer of the Company and the Bank, effective December 2, 2024.
On November 11, 2024, Shawn Munsell gave notice of his resignation from his position as Chief Financial Officer of Calavo Growers, Inc. (“Calavo”), effective November 29, 2024.
Patricia B. Prichep, CEL-SCI’s current senior Vice President of Operations, has assumed the duties of CEL-SCI’s Chief Financial and Operations Officer, effective November 13, 2024.
On November 11, 2024, Michael Kuta notified DMC Global Inc. (the “Company”) that he will retire as the Company’s President and Chief Executive Officer and as a member of the Board of Directors (the “Board”), in each case effective as of November 29, 2024 (the “Transition Date”).
On November 12, 2024, the Board appointed James O’Leary, the Company’s Executive Chairman, as the Company’s Interim President and Chief Executive Officer, effective as of the Transition Date.
Appointed
Frank Cesario
Chief Financial Officer, Vice President Finance, Treasurer and Secretary
SIGMATRON INTERNATIONAL INC
Effective
2024-11-11
Filed
November 14, 2024, 6:59 PM ET
Effective November 11, 2024, Frank Cesario was elected Chief Financial Officer, Vice President Finance, Treasurer and Secretary of the Company.
Departed
James J. Reiman
Chief Financial Officer
SIGMATRON INTERNATIONAL INC
Effective
2024-11-08
Successor
Frank Cesario
Filed
November 14, 2024, 6:59 PM ET
On November 8, 2024, the Board of Directors (the “Board”) of SigmaTron International, Inc. (NASDAQ: SGMA), an electronic manufacturing services company (the “Company”), received notice that James J. Reiman, Chief Financial Officer of the Company, was resigning for personal reasons, effective November 8, 2024.
As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.
Role change
James B. Breitmeyer
Chief Executive Officer
Oncternal Therapeutics, Inc.
Effective
2024-12-02
Filed
November 14, 2024, 6:59 PM ET
In connection with the workforce reduction, James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent will transition to part-time employment status, reducing their time commitment to 50% of their current duties effective December 2, 2024.
Departed
Mahesh Karande
President and Chief Executive Officer
Omega Therapeutics, Inc.
Effective
2024-11-14
Successor
Kaan Certel
Filed
November 14, 2024, 6:59 PM ET
On November 14, 2024 (the " Transition Date "), Mahesh Karande tendered his resignation as President and Chief Executive Officer and as a member of the Board of Directors (the " Board ") of the Company, effective immediately.
Appointed
Kaan Certel
President and Chief Executive Officer
Omega Therapeutics, Inc.
Effective
2024-11-14
Filed
November 14, 2024, 6:59 PM ET
On the Transition Date, the Board appointed Kaan Certel, Ph.D., the Company’s Chief Business Officer, to serve as the Company’s President and Chief Executive Officer and elected Dr. Certel to serve as a Class I director to fill the vacancy on the Board created by Mr. Karande’s resignation, in each case, effective immediately.
Departed
Kirk Coleman
Chief Financial Officer
TFF Pharmaceuticals, Inc.
Effective
2024-11-14
Successor
Craig R. Jalbert
Filed
November 14, 2024, 6:59 PM ET
Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.
Departed
Harlan Weisman
President/Chief Executive Officer
TFF Pharmaceuticals, Inc.
Effective
2024-11-14
Successor
Craig R. Jalbert
Filed
November 14, 2024, 6:59 PM ET
Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.
the Board appointed Craig R. Jalbert, age 63, as the Company's President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and sole member of the Board, effective November 14, 2024.
the Company announced the appointment of Jed Latkin, age 50, a current member of the Board, to serve as the Company’s President and Chief Executive Officer, effective as of the Transition Date.
Departed
Linda Stacy
Secretary, Principal Financial Officer, and Principal Accounting Officer
On November 8, 2024, Linda Stacy, Secretary, Principal Financial Officer, and Principal Accounting Officer of National Research Corporation (the “Company”), notified the Company of her decision to retire effective December 31, 2024.
Mr. Neal Goldman, the Chairman of the Board of Directors of the Company, has been appointed the Interim Chief Executive Officer, effective on Mr. Haverhals retirement.
On November 8, 2024, Mr. Arjan Haverhals, the Chief Executive Officer of Milestone Scientific Inc. (the “Company”), advised the Chairman of the Board that he intends to retire as an officer from the Company upon the expiration of, and not seek the renewal of, his employment agreement, on December 31, 2024.
on November 11, 2024 the Board appointed Paul Richards as the Company’s Chief Financial Officer, Executive Vice President-Finance, Assistant Secretary and Treasurer effective as of 12:00 a.m. Central Time on January 1, 2025.
On November 11, 2024, Brian Mitts resigned effective as of 11:59 p.m. Central Time on December 31, 2024 from his positions as Chief Financial Officer, Executive Vice President-Finance, Secretary and Treasurer of NexPoint Real Estate Finance, Inc.
Appointed
Paul Richards
Chief Financial Officer, Executive VP-Finance, Treasurer and Assistant Secretary
the Board appointed Paul Richards as the Company’s Chief Financial Officer, Executive VP-Finance, Treasurer and Assistant Secretary, effective as of 12:00 a.m. Central Time on January 1, 2025.
Departed
Brian Mitts
Chief Financial Officer, Executive VP-Finance, Secretary and Treasurer
Brian Mitts resigned effective as of 11:59 p.m. Central Time on December 31, 2024 from his positions as Chief Financial Officer, Executive VP-Finance, Secretary and Treasurer of NexPoint Residential Trust, Inc.
Appointed
Paul Richards
Chief Financial Officer, Executive VP-Finance, Treasurer and Assistant Secretary
the Board appointed Paul Richards as the Company’s Chief Financial Officer, Executive VP-Finance, Treasurer and Assistant Secretary, effective as of 12:00 a.m. Central Time on January 1, 2025.
Departed
Brian Mitts
Chief Financial Officer, Executive VP-Finance, Treasurer and Assistant Secretary
On November 11, 2024, Brian Mitts resigned effective as of 11:59 p.m. Central Time on December 31, 2024 from his positions as Chief Financial Officer, Executive VP-Finance, Treasurer and Assistant Secretary of NexPoint Diversified Real Estate Trust
Appointed
Elbert Michael Ussery
Chief Executive Officer
CORETEC GROUP INC.
Effective
2024-11-06
Filed
November 14, 2024, 6:59 PM ET
Elbert Michael Ussery, age 73, will serve as the Chief Executive Officer and Co-Chairman of the Board, effective November 6, 2024.
Role change
Seon Kee Kim
Chief Executive Officer
CORETEC GROUP INC.
Effective
2024-11-06
Successor
Elbert Michael Ussery
Filed
November 14, 2024, 6:59 PM ET
Effective November 6, 2024 Dr. Seon Kee Kim resigned as the Chief Executive Officer of the Company, but remains on the board of directors as its co-chairman and as a director.
Role change
Robert Mattacchione
Chief Executive Officer
Novo Integrated Sciences, Inc.
Effective
2025-02-05
Filed
November 14, 2024, 6:59 PM ET
On November 7, 2024, Robert Mattacchione resigned as Chief Executive Officer of Novo Integrated Sciences, Inc. (the “Company”), effective 90 days following the notification date (i.e. effective February 5, 2025).
In connection with his appointment as Interim Chief Executive Officer, Mr. Lin will receive an additional $15,000 for each month he serves as Interim Chief Executive Officer.
Christopher Geberth, Chief Financial Officer of Allurion Technologies, Inc. (the “Company”), notified the Company of his decision to resign, effective as of the close of business on November 13, 2024, to pursue other interests.
On October 1, 2024, Dave Bruce was terminated as the Company’s Chief Executive Officer (the “CEO”) and principal executive officer, effective immediately
Mr. Maffei, the President and Chief Executive Officer, and a member of the Board of Directors of Liberty Broadband, notified Liberty Broadband that he will be stepping down from these roles at the end of 2024.
Appointed
Clint Hinds
Chief Executive Officer and President
BGO Industrial Real Estate Income Trust, Inc.
Effective
2024-12-31
Filed
November 13, 2024, 6:59 PM ET
appointed Clint Hinds to serve as the Company’s Chief Executive Officer and President, effective December 31, 2024.
Departed
Michael Glimcher
Chief Executive Officer and President
BGO Industrial Real Estate Income Trust, Inc.
Effective
2024-12-31
Successor
Clint Hinds
Filed
November 13, 2024, 6:59 PM ET
Mr. Glimcher delivered his notice of resignation to the Board on November 6, 2024, with an effective date of December 31, 2024 or such earlier date with notice thereof.
Appointed
John Gillings
principal financial officer and principal accounting officer
On November 13, 2024, Strata Skin Sciences, Inc. (the “Company”) designated its Vice President Finance, John Gillings, as its principal financial officer and principal accounting officer.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.